Researchers from Charité–Universitätsmedizin Berlin offer a possible explanation of why women suffer migraines at triple the rate that men do. In a study published recently in Neurology, they reveal that women who experience migraines have higher levels of CGRP, which is known to play an important role in triggering migraines, during menstruation.
“Animal models suggest that fluctuations in female hormones, especially estrogen, lead to an increased release of CGRP, an inflammatory neurotransmitter, in the brain,” explains study lead Dr. Bianca Raffaelli. “CGRP’s full name is calcitonin gene-related peptide. It is a naturally occurring substance in the body, and when a person has a migraine attack, increasing levels are released, significantly dilating, or widening, the blood vessels in the brain. This causes an inflammatory response that could be one of the reasons behind the severe headaches people experience with migraine.”
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
The team studied a total of 180 women to determine whether the link between female hormones and the release of CGRP also exists in humans. The researchers tested the CGRP levels in migraine patients twice during their cycle, with one measurement taken during menstruation and the other during ovulation. When the data were compared to those of women who do not suffer migraines, it became clear that migraine patients have significantly higher concentrations of CGRP during menstruation than healthy subjects.
“This means that when estrogen levels drop immediately before the start of a menstrual period, migraine patients release more CGRP,” says Raffaelli. “This could explain why these patients suffer more migraine attacks just before and during their monthly period.”
In women who take oral contraception, by contrast, there are hardly any fluctuations in estrogen levels. As researchers showed in this study, CGRP concentrations are also uniform over the course of the “artificial cycle” caused by oral contraception, with comparable levels seen in both female migraine patients and healthy women. The researchers made a similar observation in postmenopausal women.
“The data will still need to be confirmed by larger studies, but our findings do suggest that the release of CGRP depends on hormonal status in humans, as it does in the animal model,” Raffaelli notes. “Taking birth control pills and the end of menopause do in fact bring relief for some female migraine patients. But as our study also shows, there are women who suffer from migraine even without any hormonal fluctuations. We suspect that other processes in the body play a role in triggering attacks in those patients. After all, CGRP isn’t the only inflammatory peptide that can cause a migraine attack.”